Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
用户CFC_oBVxWvXo
5个月前
156
10
已完结
1. 系统已在2025-05-01 11:12:10对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/S0140-6736(23)01053-X
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S014067362301053X
其他信息:
出版社: Elsevier BV
作者: Julio Rosenstock; Juan Frias; Ania M Jastreboff; Yu Du; Jitong Lou; Sirel Gurbuz; Melissa K Thomas; Mark L Hartman; Axel Haupt; Zvonko Milicevic; Tamer Coskun
